The State Food and Drug Administration has authorized three Hong Kong hospitals to undertake clinical tests for mainland corporate clients, according to a circular issued here Friday.
The decision is part of an agreement between the administration and the Health Department of the Hong Kong Special Administrative Region aimed at enhancing cooperation in drug authentication.
Starting from this month, the Prince of Wales Hospital, Queen Mary Hospital and Hong Kong Eye Hospital may conduct clinical tests for mainland companies that have registered new drugs with the administration.
Test results by these hospitals will be recognized by drug authorities both on the mainland and in the special administrative region.
According to the circular, the Prince of Wales Hospital is authorized to conduct clinical tests on drugs relating to digestion, tumors, internal secretion, ophthalmology and some paediatric diseases.
The Queen Mary Hospital will focus on heart and blood vessels, respiration, liver transplants, gynaecology and obstetrics, blood and marrow transplant while the Hong Kong Eye Hospital is devoted to eye diseases.
Source: China View